8-chloro-5H-<1>benzopyrano<2,3-b>pyridin-5-one | 54629-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 8-chloro-5H-<1>benzopyrano<2,3-b>pyridin-5-one
• 英文别名: 8-chloro-chromeno[2,3-b]pyridin-5-one；8-chloro-5H-chromeno[2,3-b]pyridin-5-one；8-chlorochromeno[2,3-b]pyridin-5-one
• CAS: 54629-17-3
• 化学式: C₁₂H₆ClNO₂
• 分子量: 231.638
• InChiKey: SFSWTHUKMYYFFD-UHFFFAOYSA-N

物化性质

• 熔点：
  189-190 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  413.4±45.0 °C(Predicted)
• 密度：
  1.458±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-chloro-5H-<1>benzopyrano<2,3-b>pyridin-5-one 在 氢氧化钾 、 盐酸羟胺 作用下， 以 乙醇 为溶剂， 生成 3-(6-chloro-benzo[d]isoxazol-3-yl)-1H-pyridin-2-one
  参考文献：
  名称：

  Benzopyranopyridine derivatives. 2. Reaction of azaxanthones with hydroxylamine

  摘要：

  DOI：

  10.1021/jo00900a012
• 作为产物：
  描述：

  2-(3-氯-苯氧基)-烟酸 生成 8-chloro-5H-<1>benzopyrano<2,3-b>pyridin-5-one
  参考文献：
  名称：

  Benzopyranopyridine derivatives. 1. Aminoalkyl derivatives of the azaxanthenes as bronchodilating agents

  摘要：

  The preparation of the four isomeric azaxanthones 3 and a number of their aromatic ring substituted derivatives is described. These ketones were converted into the title compounds which were examined for their biological properties. The most interesting compound in this series, the 1-methyl-4-piperidylidene derivative of 1-azaxanthene, shows the profile of an orally effective potent bronchodilating agent as well as a moderate antihistamine. Biological properties of this compound were compared to a number of antihistamines as well as known bronchodilating agents. Structure-activity relationships are also discussed.

  DOI：

  10.1021/jm00235a001

文献信息

• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Weinstein David S.

  公开号：US20090075995A1

  公开（公告）日：2009-03-19

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R 5 , R 6 , R 7 , and R 8 ; J 1 , J 2 , and J 3 are at each occurrence the same or different and are independently -A 1 QA 2 -; Q is a bond, O, S, S(O), or S(O) 2 ; A 1 and A 2 are the same or different and are at each occurrence independently selected from a bond, C 1-3 alkylene, substituted C 1-3 alkylene, C 2-4 alkenylene, and substituted C 2-4 alkenylene, provided that A 1 and A 2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R 1 to R 11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了一系列新颖的非甾体化合物，这些化合物在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中很有用，包括炎性和免疫疾病，具有以下结构式（I）： 其对应的光学异构体、对映异构体或互变异构体，或其前药酯，或其药用可接受盐，其中： Z是杂环或杂芳基； A是一个5至8成员的碳环或一个5至8成员的杂环； B是一个环烷基、环烯基、芳基、杂环或杂芳基环，其中每个环都与A环上的相邻原子融合，并且可以选择性地被一个到四个独立选自R5、R6、R7和R8的相同或不同的组取代； J1、J2和J3每次出现时相同或不同，独立地选自-A1QA2-；Q是键、O、S、S(O)或S(O)2；A1和A2相同或不同，每次出现时独立地选自键、C1-3烷基、取代的C1-3烷基、C2-4烯基和取代的C2-4烯基，前提是A1和A2的选择使得环A是一个5至8成员的碳环或杂环； R1至R11如本文所述定义。 还提供了使用这些化合物的药物组合物和治疗炎性疾病、免疫相关疾病、肥胖和糖尿病的方法。
• Synthesis of Pyrido(3',2':5,6)pyrano(4,3,2-de)quinoline.
  作者：Hidetoshi FUJIWARA、Ichizo OKABAYASHI

  DOI：10.1248/cpb.41.1163

  日期：——

  Pyrido[3', 2' : 5, 6]pyrano[4, 3, 2-de]quinoline (1), which can be regarded as a combined structure of a xanthene analog and quinoline, was synthesized starting from 6-amino-5H-[1]benzopyrano[2, 3-b]pyridin-5-one (2).

  Pyrido[3', 2' : 5, 6]pyrano[4, 3, 2-de]quinoline（1），可以视为一个联结了香豆素类似物和喹啉的结构，是以6-氨基-5H-[1]苯基吡喃[2, 3-b]吡啶-5-酮（2）为起始物合成的。
• Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：US08034940B2

  公开（公告）日：2011-10-11

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R5, R6, R7, and R8; J1, J2, and J3 are at each occurrence the same or different and are independently -A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3alkylene, substituted C1-3alkylene, C2-4alkenylene, and substituted C2-4alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了新型非甾体化合物，其在治疗与葡萄糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病方面具有用途，包括炎症和免疫疾病，其具有以下结构（I）的构造： 其中，Z是杂环或杂环芳基；A是5-至8-成员的碳环或5-至8-成员的杂环；B是环烷基，环烯基，芳基，杂环芳基或杂环，其中每个环在相邻原子上与A环融合，并且可选地被一个到四个相同或不同的基团取代，这些基团是独立地从R5、R6、R7和R8中选择的；J1、J2和J3在每次出现时相同或不同，并且独立地是-A1QA2-；Q是键，O，S，S（O）或S（O）2；A1和A2在每次出现时相同或不同，并且独立地从键，C1-3烷基，取代的C1-3烷基，C2-4烯基和取代的C2-4烯基中选择，前提是A1和A2被选择为环A是5-至8-成员的碳环或杂环；R1到R11如本文所定义。 还提供了制药组合物和使用所述化合物治疗炎症或免疫相关疾病以及肥胖症和糖尿病的方法。
• VILLANI F. J.; MANN T. A.; WEFER E. A.; HANNON J.; LARCA L. L.; LANDON M.+, J. MED. CHEM. <JMCM-AR>, 1975, 18, NO 1, 1-8
  作者：VILLANI F. J.、 MANN T. A.、 WEFER E. A.、 HANNON J.、 LARCA L. L.、 LANDON M.+

  DOI：——

  日期：——
• MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF
  申请人：Bristol-Myers Squibb Company

  公开号：EP2049507A2

  公开（公告）日：2009-04-22